UNICHEMLABNSEUnichem Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Wed, 25 Feb · 09:21 IST

Unichem Laboratories Limited has informed the Exchange regarding Notice of Postal Ballot.

Management Changes View source PDF

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Unichem Laboratories has issued a postal ballot notice to its shareholders seeking approval for three items. First, the appointment of Dr. (Ms) Swati Patankar (DIN 06594600), currently a Professor at IIT Bombay's Department of Biosciences & Bioengineering, as a Non-Executive Independent Director for a five-year term effective February 5, 2026. Second, approval of material related party transactions between its holding company Ipca Laboratories and its wholly owned US subsidiary Unichem USA, capped at ₹400 crore for FY 2026-27. Third, approval of material related party transactions directly with Unichem USA, capped at ₹1,600 crore for FY 2026-27. The company justifies the related party transactions on grounds of group synergies, regulatory requirements in pharmaceuticals that limit supplier switching, and confidentiality of intellectual property. E-voting runs from February 26, 2026 to March 27, 2026.

Likely market impact

The proposed RPT limits of ₹400 crore (Ipca-Unichem USA) and ₹1,600 crore (Unichem-Unichem USA) are significant in scale and indicate continued operational integration within the Ipca group. Appointment of an academic with strong pharma R&D background as independent director may strengthen board oversight in technical and research matters. Shareholders should review the RPT terms to ensure they remain at arm's length.